-The PLATFORM-CM trial is evaluating oteseconazole and other investigational products against the standard of care for treating cryptococcal meningitis "We are excited to initiate this important study ...

A: An internist or infectious diseases specialist will treat cryptococcal meningitis. A: Cryptococcal paradoxical IRIS (immune reconstitution inflammatory syndrome) is a complication that arises after ...

This double-blind trial enrolled adults with HIV-associated cryptococcal meningitis in Vietnam, Thailand, Indonesia, Laos, Uganda, and Malawi. All patients received combination antifungal therapy of ...

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

Cryptococcus neoformans commonly causes opportunistic infection in immunocompromised patients, especially in patients with AIDS. The CD4+ T-lymphocyte count is measured in patients with HIV infection, ...

Cryptococcal meningitis, the second-leading cause of HIV-related deaths, is expected to rise as access to care weakens and advanced HIV disease (previously called AIDS) increases. A new, ...

Nelesh P. Govender currently receives funding from the National Institutes of Health and US Centers for Disease Control and Prevention. South Africa has launched the world’s largest national screening ...

A new, easier-to-administer and patient-friendly sustained-release formulation of flucytosine, a medicine used to treat cryptococcal meningitis, has entered Phase II clinical trials in Malawi and ...

As a result of a large randomized, controlled trial (and experience during the first 15 years of the AIDS epidemic), standard guidelines for treatment of cryptococcal meningitis recommend 2 weeks of ...

Scientists have captured video footage of meningitis as it spreads through a brain. Experts used transparent fish to watch in real-time as Cryptococcal meningitis spread through the organ. The ...

Dar es Salaam / Lilongwe / Geneva — 15 April 2025 — A new, easier-to-administer and patient-friendly sustained-release formulation of flucytosine, a medicine used to treat cryptococcal meningitis, has ...